Search This Blog

Tuesday, June 15, 2021

Eton: FDA Approves Rezipres® (Ephedrine Hydrochloride Injection)

 Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezipres® (ephedrine hydrochloride injection) for the treatment of clinically important hypotension occurring in the setting of anesthesia.

“We are excited to see the approval of Rezipres, which is now our second FDA-approved ready-to-use hospital injectable product. We believe ready-to-use injectable products provide a compelling benefit to hospitals and reduce the need for hospitals to rely on unapproved compounded products,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “This innovative sulfite-free formulation has been successfully sold in Europe for years, and we are excited to make it available to U.S. patients shortly.”

https://finance.yahoo.com/news/eton-pharmaceuticals-announces-fda-approval-143700564.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.